2026-2034年全球胃食道逆流症治疗市场规模、份额、趋势及成长分析报告

预计胃食道逆流症 (GERD) 治疗市场规模将从 2025 年的 58.3 亿美元成长到 2034 年的 75.6 亿美元，2026 年至 2034 年的复合年增长率为 2.93%。

由于全球胃酸逆流和胃肠道疾病的发生率不断上升，胃食道逆流（GERD）治疗药物的全球市场正经历着稳定成长。久坐的生活方式、不健康的饮食习惯、肥胖和压力是导致GERD病例增加的主要因素。包括质子帮浦阻断剂（PPI）和H2受体拮抗剂在内的有效药物的日益普及，正在推动市场需求的稳定成长。

关键成长要素包括诊断程序的改进、医疗保健意识的提高以及非处方药的普及。製药公司正投资研发缓释製剂和联合治疗，以提高治疗效果。已开发国家和开发中国家医疗基础设施的扩建以及老年人口的成长，也为市场进一步成长提供了支持。

未来，随着新药製剂的研发和微创治疗方法的进步，市场预计将持续扩张。标靶治疗的研究以及提高患者依从性的措施将有助于提升治疗效果。新兴市场医疗保健服务的普及和公众意识的提高，预计将为胃食道逆流（GERD）治疗药物生产商创造巨大的发展机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球胃食道逆流症治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 质子帮浦阻断剂（PPI）
• H2受体拮抗剂（H2RAs）
• 制酸剂
• 胃肠动力刺激剂
• 其他药物类别

第五章 全球胃食道逆流症（GERD）治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射药物

第六章：全球胃食道逆流症治疗市场：依阶段划分

• 市场分析、洞察与预测
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第七章 全球胃食道逆流症治疗市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球胃食道逆流症治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AstraZeneca
  • Camber Pharmaceuticals
  • Eisai
  • Johnson & Johnson
  • Onconic Therapeutics
  • Pfizer
  • Phathom Pharmaceuticals
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals
  • Viatris

The Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach USD 7.56 Billion in 2034 from USD 5.83 Billion (2025) growing at a CAGR of 2.93% during 2026-2034.

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is witnessing steady growth due to increasing incidence of acid reflux and digestive disorders globally. Sedentary lifestyles, unhealthy eating habits, obesity, and stress are major contributors to rising GERD cases. The growing availability of effective medications, including proton pump inhibitors (PPIs) and H2 receptor antagonists, is driving consistent demand.

Key growth drivers include improved diagnostic procedures, growing healthcare awareness, and easy availability of over-the-counter medications. Pharmaceutical companies are investing in extended-release and combination therapies to enhance treatment outcomes. Expanding healthcare infrastructure and rising geriatric populations in both developed and developing regions are further supporting market growth.

In the future, the market is expected to expand with the development of novel drug formulations and minimally invasive treatment options. Research into targeted therapies and improved patient compliance strategies will strengthen treatment effectiveness. Emerging markets with increasing healthcare access and awareness are projected to create significant opportunities for GERD therapeutic manufacturers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists (H2RAs)
• Antacids
• Prokinetic Agents
• Other Drug Classes

By Route of Administration

• Oral
• Injectable

By Stage

• Stage 1
• Stage 2
• Stage 3
• Stage 4

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AstraZeneca, Camber Pharmaceuticals, Eisai, Johnson Johnson, Onconic Therapeutics, Pfizer, Phathom Pharmaceuticals, Sebela Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceuticals, Viatris
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Proton Pump Inhibitors (PPIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. H2 Receptor Antagonists (H2RAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Prokinetic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY STAGE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Stage
• 6.2. Stage 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Stage 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Stage 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Stage 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Stage
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Stage
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Stage
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Stage
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Stage
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Camber Pharmaceuticals
  • 10.2.3 Eisai
  • 10.2.4 Johnson & Johnson
  • 10.2.5 Onconic Therapeutics
  • 10.2.6 Pfizer
  • 10.2.7 Phathom Pharmaceuticals
  • 10.2.8 Sebela Pharmaceuticals
  • 10.2.9 Takeda Pharmaceutical Company
  • 10.2.10 Teva Pharmaceuticals
  • 10.2.11 Viatris